CAS: 144875-48-9; 1-(4-Amino-2-(Ethoxymethyl)-1H-Imidazo[4,5-C]Quinolin-1-yl)-2-Methylpropan-2-Ol

该化合物是合成的一丁二氮基辛醇化合物,主要用于免疫性循环研究,主要用于免疫性肺部研究,作为类似收费受体(TLR) 7/8 活性剂,主要用于免疫性肺部研究,它诱发生产如脑膜-阿尔法,肿瘤坏死因子-阿尔法和脑膜间细胞,从而增强内生和适应性免疫反应. Resiquimod因其强大的抗病毒和抗直肠特性而受到重视,使它成为免疫活性,疫苗抗体和皮肤学应用研究中的一个关键工具. 它刺激登盘细胞和促进TH1型免疫反应的能力强调了它在临床和治疗研究中的效用. 化合物通常以高纯度固度供应,确保实验环境中的再生能力.

结构式图片

欧盟法规

C&L通报

上下游产品

CAS号253120-65-9 N-{2-chloro-4-[... | CAS号7440-44-0 活性炭 | CAS号133860-77-2 1-[(2-chloro-3-... | CAS号133860-78-3 1-[(3-氨基-2-氯-4-... | CAS号15151-57-2 2,4-二羟基-3-硝基喹啉 | CAS号70254-44-3 2-羟基喹啉-4(1H)-酮 | CAS号132521-66-5 2,4-二氯-3-硝基喹啉 | CAS号102-76-1 三醋酸甘油酯

合成工艺路线路线简述

  • 合成目标产物 Resiquimod 主要起始原料 N-{2-Chloro-4-[(2-Hydroxy-2-Methylpropyl)Amino]Quinolin-3-Yl}-2-Ethoxyacetamide
  • (文献来源)合成步骤主要原料 N-{2-Chloro-4-[(2-Hydroxy-2-Methylpropyl)Amino]Quinolin-3-Yl}-2-Ethoxyacetamide
📜4-Chloro-α,α-Dimethyl-2-Ethoxymethyl-1H-Imidazo[4,5-C]Quinoline-1-Ethanol置于氨体系中,用 甲醇 用作溶剂,化学反应 6.0H,反应生成雷西莫特
参考文献:1-Substituted,2-Substituted 1H-Imidazo[4,5-C]Quinolin-4-Amines
标题:1-Substituted,2-Substituted 1H-Imidazo[4,5-C]Quinolin-4-Amines
摘要:本发明揭示了1-取代,2-取代的1H-咪唑并[4,5-C]-喹啉-4-胺化合物.这些化合物作为抗病毒剂,它们诱导干扰素的生物合成,并在动物模型中抑制肿瘤形成.该发明还提供了制备这些化合物的中间体,含有这些化合物的药物组合物,以及使用这些化合物的药理学方法.

海关参考信息

专利信息


专利号:US-12188072-B2
优先权日:2018-03-19
标题 :Compositions and methods for rapid in vitro synthesis of bioconjugate vaccines in vitro via production and N-glycosylation of protein carriers in detoxified prokaryotic cell lysates
发明人:JEWETT MICHAEL CHRISTOPHER; STARK JESSICA CAROL; DELISA MATTHEW P; JAROENTOMEECHAI THAPAKORN
权利人:UNIV NORTHWESTERN; UNIV CORNELL
摘要:Disclosed are methods, systems, components, and compositions for cell-free synthesis of glycosylated carrier proteins. The glycosylated carrier proteins may be utilized in vaccines, including anti-bacterial vaccines. The glycosylated carrier proteins may include a bacterial polysaccharide conjugated to a carrier, which may be utilized to generate an immune response in an immunized host against the polysaccharide conjugated to the carrier. The glycosylated carrier proteins may be synthesized in cell-free glycoprotein synthesis (CFGpS) systems using prokaryote cell lysates that are enriched in components for glycoprotein synthesis such as oligosaccharyltransferases (OSTs) and lipid-linked oligosaccharides (LLOs) including OSTs and LLOs associated with synthesis of bacterial O antigens.

专利号:US-12365930-B2
优先权日:2016-07-14
标题:Method for rapid in vitro synthesis of glycoproteins via recombinant production of N-glycosylated proteins in prokaryotic cell lysates
发明人:JEWETT MICHAEL CHRISTOPHER; STARK JESSICA CAROL; DELISA MATTHEW P; JAROENTOMEECHAI THAPAKORN
权利人:UNIV NORTHWESTERN; UNIV CORNELL
摘要:Disclosed are methods, systems, components, and compositions for cell-free synthesis of glycosylated proteins. The glycosylated proteins may be utilized in vaccines, including anti-bacterial vaccines. The glycosylated proteins may include a bacterial polysaccharide conjugated to a carrier, which may be utilized to generate an immune response in an immunized host against the polysaccharide conjugated to the carrier. The glycosylated proteins may be synthesized in cell-free glycoprotein synthesis (CFGpS) systems using prokaryote cell lysates that are enriched in components for glycoprotein synthesis such as oligosaccharyltransferases (OSTs) and lipid-linked oligosaccharides (LLOs) including OSTs and LLOs associated with synthesis of bacterial O antigens.

专利号:US-12391691-B2
优先权日:2018-11-16
标题:Synthesis of key intermediate of KRAS G12C inhibitor compound
发明人:PARSONS ANDREW THOMAS; COCHRAN BRIAN MCNEIL; POWAZINIK IV WILLIAM; CAPORINI MARC ANTHONY
权利人:AMGEN INC
摘要:The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure n nuseful for the synthesis of compounds that target KRAS G12C mutations, such as

专利号:US-2025206736-A1
优先权日:2019-11-14
标题 :Synthesis of kras g12c inhibitor compound
发明人:CORBETT MICHAEL THOMAS; CAILLE SEBASTIEN
权利人:AMGEN INC
摘要:The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2-isopropyl-4-methylpyridin-3-amine, useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.

专利号:US-12404533-B2
优先权日:2019-01-11
标 题:Bioconjugate vaccines' synthesis in prokaryotic cell lysates
发明人:JEWETT MICHAEL CHRISTOPHER; STARK JESSICA CAROL; DELISA MATTHEW P; JAROENTOMEECHAI THAPAKORN
权利人:UNIV NORTHWESTERN; UNIV CORNELL
摘要:Disclosed are methods, systems, components, and compositions for cell-free synthesis of glycosylated proteins, which may be utilized in vaccines, including anti-bacterial vaccines. The glycosylated proteins may include a bacterial polysaccharide conjugated to a carrier, which may be utilized to generate an immune response in an immunized host against the polysaccharide conjugated to the carrier. Suitable carriers may include but are not limited to Haemophilus influenzae protein D (PD), Neisseria meningitidis porin protein (PorA), Corynebacterium diphtheriae toxin (CRM 197), Clostridium tetani toxin (TT), and Escherichia coli maltose binding protein, and variants thereof.

专利号:US-2022233673-A1
优先权日:2019-06-04
标 题:METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STxB) MONOMERS AND OLIGOMERS, AND USES THEREOF
发明人:BILLET ANNE; SCHMIDT FRÉDÉRIC; JOHANNES LUDGER; SERVENT DENIS; MOURIER GILLES; TARTOUR ÉRIC; KAY MICHAEL; FULCHER JAMES M
权利人:INST CURIE; CENTRE NAT RECH SCIENT; INST NAT SANTE RECH MED; COMMISSARIAT A LENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES CEA; APHP ASSIST PUBLIQUE HOPITAUX DE PARIS; UNIV PARIS; UNIV OF UTAH RESEARCH FOUDATION; UNIV UTAH RES FOUND
摘要:A method of producing a monomer of a Shiga toxin B-subunit (STxB) protein or of a variant thereof by peptide chemical synthesis, as well as to a method of producing a pentamer of the STxB protein or of the variant thereof. The methods are particularly advantageous as they overcome major issues typically observed in peptide chemical synthesis, including solubility and purity issues.

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Sabado RL, Pavlick A, Gnjatic S, Cruz CM, Vengco I, Hasan F, Spadaccia M, Darvishian F, Chiriboga L, Holman RM, Escalon J, Muren C, Escano C, Yepes E, Sharpe D, Vasilakos JP, Rolnitzsky L, Goldberg JD, Mandeli J, Adams S, Jungbluth A, Pan L, Venhaus R, Ott PA, Bhardwaj N. Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High-Risk Melanoma. Cancer Immunol Res. 2015 Jan 29. [Epub ahead of print] doi: 10.1016/j.molimm.2014.11.013. Epub 2014 Dec 9. doi: 10.1128/CVI.00338-14. Epub 2014 Jul 16.
4: Lee M, Park CS, Lee YR, Im SA, Song S, Lee CK. Resiquimod, a TLR7/8 agonist, promotes differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells. Arch Pharm Res. 2014 Sep;37(9):1234-40. doi: 10.1007/s12272-014-0379-4. Epub 2014 Apr 19. doi: 10.1128/AAC.00077-14. Epub 2014 Apr 7.
6: Zhou CX, Li D, Chen YL, Lu ZJ, Sun P, Cao YM, Bao HF, Fu YF, Li PH, Bai XW, Xie BX, Liu ZX. Resiquimod and polyinosinic-polycytidylic acid formulation with aluminum hydroxide as an adjuvant for foot-and-mouth disease vaccine. BMC Vet Res. 2014 Jan 3;10:2. doi: 10.1186/1746-6148-10-2.

合成参考文献


参考文献:10.1016/s1567-5769(01)00184-9
摘要:Miller RL, Tomai MA, Harrison CJ, Bernstein DI. Immunomodulation as a treatment strategy for genital herpes: review of the evidence. Int Immunopharmacol. 2002 Mar;2(4):443–51. doi: 10.1016/s1567-5769(01)00184-9.
参考文献:10.1007/s12016-004-0006-0|10.1385/criai:26:2:115
摘要:Gangloff SC, Guenounou M. Toll-like receptors and immune response in allergic disease. Clinical Reviews in Allergy & Immunology. 2004 Apr;26(2):115–25. doi: 10.1007/s12016-004-0006-0.
参考文献:10.1007/s00105-004-0744-1
摘要:Wetzel S, Wollenberg A. [Eczema herpeticatum]. Hautarzt. 2004 Jul;55(7):646–52. doi: 10.1007/s00105-004-0744-1.
参考文献:10.1186/1742-4682-3-22
摘要:Kannan S. Free radical theory of autoimmunity. Theoretical Biology and Medical Modelling. 2006 Jun 07;3(1):22. doi: 10.1186/1742-4682-3-22.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知